Physician profile
Steven Clift
NPI 1285681965
$828.65
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $11.81.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $216.48 | 2019 | |
| Braintree Laboratories, INC. | $169.37 | 2019 | |
| Pfizer INC. | $136.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.94 | 2019 | |
| Gilead Sciences, INC. | $65.86 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $64.08 | 2019 | |
| Janssen Biotech, INC. | $49.97 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.07 | 2019 | |
| Allergan, INC. | $13.88 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Clift listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.